Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Clinical Trial ID NCT00509496

Rank	Title	Journal	Year	PubWeight™‹?›
1	Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.	Proc Natl Acad Sci U S A	1994	8.92
2	Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.	Proc Natl Acad Sci U S A	1994	6.93
3	Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.	J Exp Med	1994	5.67
4	Gene-engineered T cells for cancer therapy.	Nat Rev Cancer	2013	2.07
5	Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.	Blood	2012	1.43
6	Synthetic biology in cell-based cancer immunotherapy.	Trends Biotechnol	2015	0.84
7	Genetic engineering with T cell receptors.	Adv Drug Deliv Rev	2011	0.82
8	Targeting CD8+ T-cell tolerance for cancer immunotherapy.	Immunotherapy	2014	0.81